 Phosphatidylinositol 3-Kinases
"Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
| Descriptor ID |
D019869
|
| MeSH Number(s) |
D08.811.913.696.620.500
|
| Concept/Terms |
Phosphatidylinositol 3-Kinases- Phosphatidylinositol 3-Kinases
- Phosphatidylinositol 3 Kinases
- Phosphoinositide 3-Hydroxykinase
- PI 3-Kinase
- PtdIns 3-Kinases
- 3-Kinases, PtdIns
- PtdIns 3 Kinases
- PI-3K
- PI3 Kinases
- Kinases, PI3
- PI3-Kinase
- PtdIns 3-Kinase
- Phosphatidylinositol-3-OH Kinase
- PI-3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinases" by people in UAMS Profiles by year, and whether "Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 2 | 2 | 4 | | 2022 | 0 | 1 | 1 | | 2021 | 0 | 3 | 3 | | 2019 | 2 | 1 | 3 | | 2016 | 1 | 2 | 3 | | 2015 | 1 | 0 | 1 | | 2014 | 1 | 4 | 5 | | 2013 | 0 | 2 | 2 | | 2012 | 2 | 3 | 5 | | 2011 | 1 | 1 | 2 | | 2010 | 1 | 6 | 7 | | 2009 | 2 | 2 | 4 | | 2008 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2006 | 3 | 1 | 4 | | 2005 | 3 | 0 | 3 | | 2004 | 1 | 2 | 3 | | 2003 | 1 | 1 | 2 | | 2001 | 0 | 1 | 1 | | 2000 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinases" by people in Profiles over the past ten years.
-
Jin S, Li B, Zhang B, Gao X, Jia X, Xu L, Chang S, Hu K, Wang G, Xu Z, Zhang T, Song D, Yang G, Wu X, Zhu H, Huang C, Lu Y, Shi J, Zhu W, Chen G. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation. Acta Biochim Biophys Sin (Shanghai). 2023 12 25; 55(12):1884-1891.
-
Lang M, Cai HC, Lin H, Chang L, Dai JW, Chen J, Duan MH, Zhou DB, Goyal G, Cao XX. Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis. Orphanet J Rare Dis. 2023 Nov 30; 18(1):372.
-
Hulett NA, Knaub LA, Hull SE, Pott GB, Peelor R, Miller BF, Shankar K, Rudolph MC, Reusch JEB, Scalzo RL. Sex Differences in the Skeletal Muscle Response to a High Fat, High Sucrose Diet in Rats. Nutrients. 2023 Oct 19; 15(20).
-
Alam J, Huda MN, Tackett AJ, Miah S. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer Metastasis Rev. 2023 06; 42(2):409-425.
-
Mitchell R, Chacko J. Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy. Biomolecules. 2022 09 14; 12(9).
-
Aytatli A, Barlak N, Sanli F, Caglar HO, Gundogdu B, Tatar A, Ittmann M, Karatas OF. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr). 2022 Feb; 45(1):41-56.
-
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol. 2021 10 16; 14(1):170.
-
Matsuzaki S, Eyster C, Newhardt MF, Giorgione JR, Kinter C, Young ZT, Kinter M, Humphries KM. Insulin signaling alters antioxidant capacity in the diabetic heart. Redox Biol. 2021 11; 47:102140.
-
Dimitrova D, Nademi Z, Maccari ME, Ehl S, Uzel G, Tomoda T, Okano T, Imai K, Carpenter B, Ip W, Rao K, Worth AJJ, Laberko A, Mukhina A, N?ven B, Moshous D, Speckmann C, Warnatz K, Wehr C, Abolhassani H, Aghamohammadi A, Bleesing JJ, Dara J, Dvorak CC, Ghosh S, Kang HJ, Markelj G, Modi A, Bayer DK, Notarangelo LD, Schulz A, Garcia-Prat M, Soler-Palac?n P, Karak?kc? M, Yilmaz E, Gambineri E, Menconi M, Masmas TN, Holm M, Bonfim C, Prando C, Hughes S, Jolles S, Morris EC, Kapoor N, Koltan S, Paneesha S, Steward C, Wynn R, Duffner U, Gennery AR, Lankester AC, Slatter M, Kanakry JA. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022 01; 149(1):410-421.e7.
-
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2020 02; 156(2):301-307.
-
Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 08 13; 129(10):4451-4463.
-
Mao G, Smyth SS, Morris AJ. Regulation of PLPP3 gene expression by NF-?B family transcription factors. J Biol Chem. 2019 09 20; 294(38):14009-14019.
-
Zarate YA, Boccuto L, Srikanth S, Pauly R, Ocal E, Balmakund T, Hinkle K, Stefans V, Schaefer GB, Collins RT. Constitutive activation of the PI3K-AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome. Am J Med Genet A. 2019 06; 179(6):1047-1052.
-
Koziol-White CJ, Yoo EJ, Cao G, Zhang J, Papanikolaou E, Pushkarsky I, Andrews A, Himes BE, Damoiseaux RD, Liggett SB, Di Carlo D, Kurten RC, Panettieri RA. Inhibition of PI3K promotes dilation of human small airways in a rho kinase-dependent manner. Br J Pharmacol. 2016 09; 173(18):2726-38.
-
Ruebel M, Shankar K, Gaddy D, Lindsey F, Badger T, Andres A. Maternal obesity is associated with ovarian inflammation and upregulation of early growth response factor 1. Am J Physiol Endocrinol Metab. 2016 07 01; 311(1):E269-77.
-
Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.
-
Shiver MB, Mahmoud F, Gao L. More on Merkel-Cell Carcinoma. N Engl J Med. 2016 02 04; 374(5):495.
-
Shiver MB, Mahmoud F, Gao L. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma. N Engl J Med. 2015 Oct 15; 373(16):1580-2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|